Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer

Cancer

Volumn 71, Issue 3 S, 1993, Pages 1098-1109

  Yagoda, Alan ^a   Petrylak, Daniel ^a  

^a Department of Orthopaedic Surgery   (United States)

Author keywords

cytotoxic chemotherapy; new agents; Phase II trials; prostate cancer

Indexed keywords

AMSACRINE; ANGIOPEPTIN; ANTIMITOTIC AGENT; BISANTRENE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESORUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; FOLIC ACID ANTAGONIST; IFOSFAMIDE; INTERCALATING AGENT; POLYAMINE DERIVATIVE; PYRIMIDINE ANTAGONIST; UNINDEXED DRUG;

BONE METASTASIS; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER REGRESSION; CONFERENCE PAPER; CYTOTOXICITY; DRUG EFFICACY; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; MULTIDRUG RESISTANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CISPLATIN; CLINICAL TRIALS; COUMARINS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FLUOROURACIL; HUMAN; INTERCALATING AGENTS; MALE; METHOTREXATE; NEOPLASM STAGING; POLYAMINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REMISSION INDUCTION; SOMATOSTATIN;

EID: 0027532535     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G     Document Type: Article

References (63)

1. Non‐hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma
2. A critical analysis of response criteria in patients with prostate cancer treated with cis‐diamminedichlori de platinum II
3. Cytotoxic agents in prostate cancer: an enigma
4. Chemotherapy for prostatic carcinoma
5. Clinical trials in prostatic cancer: methodologies and controversies
6. Non‐hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs
7. Cancer statistics, 1991
8. Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma
9. Cytotoxic chemotherapy for advanced cancer of the prostate: Memorial Sloan‐Kettering Cancer Center experience
10. Randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine unresponsive metastatic prostatic carcinoma
11. Approaches to advanced prostate cancer at Stanford University
12. Dose response evaluation of Adriamycin in human neoplasia
13. Immunoperoxidase localization of prostatic antigens: comparison of primary and metastatic sites
14. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is always an accurate indicator of disease status?
15. Effect of suramin on human prostate cancer cells in vitro
16. Trimetrexate in prostatic cancer: preliminary observations of the use of the prostate specific antigen and acid phosphatase as a marker in measurable hormone refractory disease
17. Suramin in hormone resistant metastatic prostate cancer: significant anticancer activity but unanticipated toxicity [abstract]
18. Prostate cancer presenting with pulmonary manifestations [abstract]
19. Somatostatin analogue BIM 23014 (somatuline) in prostate cancer [abstract]
20. A phase II study of Sandostatin in metastatic carcinoma of the prostate (CaP) [abstract]
21. Phase II trial of ifosfamide (IFO) in hormone refractory metastatic cancer of the prostate (HRMCP) [abstract]
22. Phase II evaluation of weekly cisplatin metastatic hormone resistant prostate cancer: a Southeastern Cancer Study Group trial
23. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer refractory to hormonal therapy: an Eastern Cooperative Oncology Group pilot study
24. Treatment of hormone refractory stage D prostate carcinoma with CHIP (NSC #256927) [abstract]
25. Phase II study of spirogermanium in metastatic prostate cancer
26. Cancer de la prostate metastatique: etude de phase II du spirogermanium (NSC 192965)
27. Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover
28. Long term continuous infusion (CI) of 5–fluorouracil (5–FU) in the treatment of metastatic prostate cancer: a phase II Mid‐Atlantic Oncology Group (MAOP) study [abstract]
29. Evaluation of 5–fluorouracil infusion (5–FUI) and cisplatin‐based combination chemotherapy in the treatment of patients (pts) with D2 hormone refractory adenocarcinoma of the prostate (HRCP) [abstract]
30. High‐dose 24 hour infusion of 5–fluorouracil in metastatic prostate cancer: a phase II trial of the Piedmont Oncology Association
31. Treatment of metastatic hormone‐resistant prostate cancer (HRPC) with sequential leucovorin (LV) and 5–fluorouracil (5–FU) [abstract]
32. Continuous FUDR for hormone refractory prostate cancer: a phase I/II study [abstract]
33. Hormone refractory metastatic prostate cancer treated with methotrexate, cyclophosphamide and Adriamycin, cisplatin plus 5–fluorouracil plus cyclophosphamide: National Prostate Cancer Project randomized trial
34. Phase II trials of 4′deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer
35. Hormone‐resistant metastatic prostate cancer: comparisons between estramustine phosphate and low‐dose epirubicin treatments
36. European Organization Research To Conquer Cancer (EORTC) phase II study of low‐dose weekly epirubicin in metastatic prostate cancer
37. Phase II trial of AMSA (4[9–acridinylaminomethanesulfon‐m‐anisidide])
38. M‐AMSA in disseminated prostatic carcinoma: a Phase II study
39. Fourteen day constant infusion of mitoxantrone HCL for hormone refractory carcinoma of the prostate (HRCaP): a pilot dose study finding [abstract]
40. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer
41. Bisantrene in advanced, hormone‐resistant carcinoma of the prostate: an Illinois Cancer Council phase II study
42. Phase II trial of amonafide in advanced prostate cancer: a Southwest Oncology Group study [abstract]
43. Amonafide in advanced hormone‐resistant prostate cancer (HRPC): an Illinois Cancer Council phase II study [abstract]
44. Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease
45. Phase II trial of etoposide in advanced prostate cancer
46. Phase II study of etoposide for carcinoma of the prostate
47. Continuous infusion of vinblastine for advanced hormone refractory prostate cancer
48. Preliminary results of a phase II trial of estramustine (Emcyt) and vinblastine (VLB) for patients (pts) with progressive hormone refractory prostate carcinoma (HRPC) [abstract]
49. Estramustine and vinblastine: effects on serum prostate specific antigen in hormonerefractory prostate cancer [abstract]
50. Oral estramustine phosphate (NSC‐89199) in the treatment of advanced (stage D) carcinoma of the prostate
51. Expression and partial characterization of estramustine‐binding protein (EMBP) in human breast cancer and malignant melanoma
52. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents
53. Estramustine binds a MAP‐1 like protein to inhibit microtubular assembly in vitro and disrupt microtubule organization in DU 145 cells
54. Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype
55. Activity of various amphiphilic agents in reversing multidrug resistance of L1210 cells
56. Methyl glyoxal‐bis guanylhydrazone (MGBG): an active drug in prostate cancer
57. Phase II evaluation of mitoguazone in metastatic hormone resistant prostate cancer: a Southeastern Cancer Group trial
58. Phase I trial of alpha‐di‐fluoromethyl ornithine (DFMO) and methylglyoxal bis guanylhydrazone (MGBG) in patients with advanced prostatic cancer
59. Phase I‐II trial of alpha‐difluoromethyl ornithine (DFMO; MDL 71,782) and mitoguazone in hormone refractory prostatic cancer (PC) [abstract]
60. Treatment of hormone refractory stage D carcinoma of the prostate with coumarin (1,2 benzopyrone) and cimetidine: a pilot study
61. National Prostatic Cancer Treatment Group. Interferon‐beta treatment of metastatic prostate cancer
62. Immunoscintigraphy of prostate cancer: preliminary results with 'In‐labelled monoclonal antibody 7E11–C5.30.2% (CYT‐356)